Background. The MitraClip REALISM (Abbott Vascular, Menlo Park, CA) trial included several inclusion criteria to identify patients at high risk for conventional mitral valve (MV) surgery. This study evaluated contemporary surgical outcomes for high-risk surgical patients who met these defined criteria to serve as a benchmark to evaluate appropriateness in treatment allocation between surgical and percutaneous MV repair.
Methods. A statewide Society for Thoracic Surgeons (STS) database was queried for patients undergoing isolated mitral valve surgery over a 12-year study period from 17 different hospitals. Patients were stratified into high-risk (HR) versus non-high-risk (non-HR) cohorts based upon clinical criteria similar to those utilized in the REALISM trial. Mixed effects multivariable regression modeling was used to evaluate study endpoints including mortality, morbidity, and resource utilization.
Results. Of 2,440 isolated mitral operations, 29% (n [ 698) were HR per REALISM criteria. Median STS Predicted Risk of Mortality (PROM) for HR patients was 6.6% compared with 1.6% for non-HR patients (p < 0.001). The HR patients more commonly underwent MV replacement as well as urgent (30% vs 19%, p < 0.001) operations. Highrisk patients incurred higher morbidity and mortality (7% vs 1.6%) with longer intensive care unit (48 vs 41 hours) and hospital stays (7 vs 6 days, all p < 0.001). Among RE-ALISM criteria, STS PROM 12% or greater and high-risk STS criteria were the only criteria associated with mortality.
Conclusions. Select REALISM criteria, including reoperation with patent grafts and functional MR with ejection fraction less than 0.40, may not identify patients truly at high risk of death with surgery. In addition to conventional STS criteria, risk assessment by surgeons is essential to direct appropriate treatment allocation for high-risk mitral disease. The clear benefit of MV surgery over medical management for severe mitral regurgitation (MR) is reflected in current guidelines published by both the joint American College of Cardiology/American Heart Association (ACC/AHA) as well as the European Society of Cardiology [1, 2] . Despite these benefits, only 50% of patients meeting ACC/AHA guidelines for surgical treatment undergo surgery due to inadequate education and counseling or misperceptions of excessively high risk associated with surgery [3, 4] .
During the past decade, significant improvements in technology have led to the development of percutaneous catheter-based MV repair. The MitraClip (Abbott Vascular, Menlo Park, CA) edge-to-edge repair device is the only percutaneous MV repair system currently available. This device has been evaluated in head-to-head evaluations with surgical MV repair. The EVEREST [Endovascular Valve Edge-to-Edge Repair] II trial established the safety for MitraClip compared with conventional MV surgery [5] . However, analyses have also demonstrated that MV surgery provides superior MR reduction compared with MitraClip [6] [7] [8] [9] [10] . The recently published REALISM trial investigated patients with severe MR deemed "high risk" for surgery using several prespecified inclusion criteria [11] . Results from this trial ultimately led to recent commercial approval of MitraClip for degenerative MR who are deemed "too high risk" for surgery [12] . Considering that many centers have demonstrated excellent outcomes for MV surgery in high-risk patients, the exact criteria used to identify truly "high-risk" patients for surgery as a referral source for percutaneous alternatives remains unclear.
The purpose of this study was twofold: (1) to evaluate contemporary surgical outcomes for high-risk patients undergoing MV repair or replacement to serve as a clinical benchmark; and (2) to evaluate the appropriateness of high-risk clinical criteria used in REALISM to determine treatment allocation and recommendations for patients with severe MR. We hypothesized that several of the high-risk criteria utilized in the REALISM trial are not associated with risk-adjusted mortality in patients undergoing mitral valve surgery.
Material and Methods
This investigation was exempt from formal Institutional Review Board review at each participating center as it represents a secondary analysis of the Virginia Cardiac Surgery Quality Initiative (VCSQI) data registry with the absence of Health Insurance Portability and Accountability Act patient identifiers and because the data are collected for quality analysis and purposes other than research.
Patients and Data Acquisition
De-identified patient records for isolated mitral valve operations were evaluated from the VCSQI database for the study period January 1, 2001 thru December 31, 2012. The VCSQI is a voluntary consortium of 17 different cardiac surgical centers within Virginia that voluntarily collaborate to improve cardiac surgical care, quality, and costs. This group exchanges and compares de-identified clinical data. Each center individually contributes patient data to the national Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database. Excluded patient records included those with missing calculated STS Predicted Risk of Mortality (PROM) as well as a history of endocarditis. Patient records were stratified into high risk (HR) versus non-high-risk (non-HR) study cohorts based upon clinical criteria similar to those utilized in the REALISM trial [11] . All mitral valve operations represent standard surgical approaches. Patient preoperative risk was assessed by individual calculated STS PROM.
Measured Outcomes
The primary outcomes of interest included risk-adjusted associations between the likelihood of operative mortality and REALISM criteria used to define HR status for mitral operations. Secondary outcomes included unadjusted differences in the prevalence of preoperative patient risk profiles and operation-related characteristics as well as the incidence of postoperative morbidity, mortality, and hospital resource utilization. Standard STS definitions for preoperative variables (prior documented history of heart failure), postoperative events, and complications were utilized, including prolonged ventilation (>24 hours of mechanical ventilation), presence of any new onset atrial fibrillation, and renal failure (increase in serum creatinine level > 2.0 or a doubling (2Â) of the most recent preoperative creatinine level) [13] .
Statistical Analysis
All study outcomes and data comparisons were established a priori before data collection. Multivariable generalized linear mixed effects regression modeling was used to estimate confounder-adjusted associations between the main effects of modeled predictor variables (various selection criteria for HR mitral valve operation status) and the likelihood of the dependent outcome (operative mortality). Modeled predictor variables (STS PROM score > 12%, ! 3 STS high-risk factors, functional MR þ EF < 0.40, age ! 75 þ EF < 0.40, reoperations with patent grafts, or ! 2 prior chest surgeries) were selected based upon established use as selection criteria for percutaneous MV repair and high-risk surgical status in the REALISM trial. The model was adjusted for the main effect of each modeled factor as well as the random (or mixed) effect of varying hospitals included in the multi-institution study cohort. The relative strength of association between modeled factors and the dependent outcome of interest was determined by quantifying each factors likelihood ratio (z statistic) within the logistic regression model. Results of model are reported as likelihood ratios, adjusted odds ratios (AOR) with 95% confidence intervals. Model discrimination performance was assessed using the models' C statistic. All statistical analyses were conducted using R statistical software, version 2.12.1 (http://www.R-project.org). Table 1 displays patient characteristics and risk factors for all patients undergoing isolated mitral valve operations (n ¼ 2,440) stratified by HR operative status. Overall, 29% (n ¼ 698) met REALISM criteria for HR mitral valve status. High-risk patients were on average slightly older (62 vs 58 years). The HR patients also presented with a higher burden of preoperative comorbid disease including hypertension, diabetes, dyslipidemia, renal failure, hemodialysis requirements, prior myocardial infarction, heart failure, and advanced New York Heart Association functional class (all p < 0.05). As a result, HR patients expectedly demonstrated higher median STS PROM (6.6% vs 1.8%, p < 0.001) compared with non-HR patients. Table 2 displays differences in operative features between groups. The HR patients more commonly underwent mitral repair operations (60.7% vs 50.9%, p < 0.001) as well as urgent (29.9% vs 19.0%, p < 0.001) and emergent (3.2% vs 1.0%, p < 0.001) operations compared with non-HR patients. Table 3 displays the frequency of REALISM high-risk inclusion criteria. Overall, the presence of functional mitral regurgitation with concomitant ejection fraction less than 0.40 was most common (57%), followed by calculated STS PROM greater than 12% (38%) and reoperation with patent bypass grafts (25%).
Results

Differences in Patient Characteristics and Operative Features
Unadjusted Comparisons of Postoperative Morbidity, Mortality, and Hospital Resource Utilization Table 4 displays unadjusted differences in postoperative morbidity, mortality, and resource utilization between HR and non-HR patients. The HR patients incurred a higher incidence of readmission to the intensive care unit, atrial fibrillation, cardiac arrest, gastrointestinal events, pneumonia, prolonged mechanical ventilation (> 24 hours), renal failure, and new onset hemodialysis (all p < 0.001). No significant differences were observed in deep sternal wound infection rates or need for reoperation. Operative mortality was approximately 4 times higher among HR patients compared with non-HR patients (7.0% vs 1.7%). The HR patients also accrued longer median intensive care unit (48 vs 41 hours, p < 0.0001) and postoperative (7 vs 6 days, p < 0.001) lengths of stay. Figure 1 displays the incidence of operative mortality stratified by HR criteria.
Adjusted Associations Between Operative Mortality and High-Risk REALISM Selection Criteria
To determine the association between high-risk REALISM criteria and operative mortality, unadjusted as well as adjusted associations between REALISM criteria and the likelihood for operative mortality were estimated using multiple regression methodology (Table 5) . Upon univariate modeling, STS PROM greater than 12%, reoperation with patent grafts, and the presence of STS high-risk criteria were all associated with operative mortality (all p < 0.001). In addition, when EF alone was modeled as a continuous function, a significant relationship was demonstrated with a small reduction in the odds of death with increasing ejection fraction (UOR: 0.97 [0.96 to 0.99], p ¼ 0.007). After accounting for the confounding influence of correlated events within hospitals using a mixed effects regression model, 2 of 6 selection criteria 
Comment
The present study reports upon the impact of high-risk surgical status on surgical isolated mitral valve repair and replacement as well as the adjusted associations that exist between select REALISM trial criteria for high-risk surgical status and observed surgical mortality. In this multi-institution cohort analysis of more than 2,440 surgical patients over a 10-year study period, high-risk patients had an operative mortality of 7%, and mitral replacement was more commonly performed compared with repair. Moreover, among high-risk REALISM criteria used to select patients for percutaneous mitral repair, there were significant variations in the riskadjusted associations with mortality in this surgical cohort, including several criteria that had little to no association with mortality. These results highlight the importance of surgeon involvement in the decisionmaking processes related to candidacy for percutaneous versus surgical mitral repair and treatment allocation for patients with mitral disease. High-risk mitral valve surgery has been the focus of an increasing body of literature, including a recent STS Adult Cardiac Surgery Database analysis of 77,836 patients, which stratified outcomes for isolated MV repair by predicted surgical risk (2002 to 2010) [14] . In this analysis, MV repair rates were noted to have increased over time, while significant reductions in operative mortality were observed for patients with STS PROM greater than 8%. Reported operative mortality rates for MV repair among patients with STS PROM 8% to 12% and PROM greater than 12% were 7.9% and 16.8%, respectively. Similarly, operative mortality rates for MV replacement among patients with STS PROM 8% to 12% and PROM greater than 12% were 9.2% and 20.1%, respectively. These results are consistent with those of the present study, which demonstrated an operative mortality rate of 20% for patients undergoing mitral repair or replacement with STS PROM greater than 12%. However, while STS PROM greater than 12% remains one of the criteria used in the REALISM trial, this criteria alone accounted for only 38% of the high-risk patients analyzed in this study. The significantly lower operative mortality reported for all high-risk patients (7%) in this series suggest that the influence of other REALISM criteria may be a result of inaccurate assessments of those with truly increased operative risk.
The principal findings of this study concern the riskadjusted associations estimated for high-risk REALISM criteria and surgical mortality. Only 2 criteria that demonstrated a significant relationship with operative mortality were the following: (1) an STS PROM score greater than 12%; and (2) the presence of 3 or greater STS high-risk factors (Cr > 2.5 mg/dL, prior chest surgery, age > 75 years, EF < 0.35). Overall, the combined frequency of these criteria accounted for only 40% of the patients analyzed in the high risk surgical cohort. These results, therefore, imply that the other REALISM criteria utilized to identify nearly 60% of high-risk patients in this study may not reliably correlate with true surgical mortality. These results are supported even further by the observation that the combined mortality for the 60% patients meeting all other high-risk REALISM criteria was 4.7%. Thus, there exists a legitimate potential for patients to undergo percutaneous mitral repair due to a perceived high-risk status for surgery when they may, in fact, be better candidates for a more durable surgical mitral procedure. In contrast, certain REALISM criteria not assessed in this study include the presence of a porcelain aorta, prior mediastinal radiation, previous mediastinitis, and the presence of hepatic cirrhosis as these are not captured in the STS database. Other criteria that surgeons use in evaluating surgical risk include pulmonary hypertension, right ventricular function, and overall frailty. As such, surgeon involvement in treatment allocation decisions for percutaneous versus surgical mitral valve repair or replacement remains critical.
This study has limitations. The retrospective study design is subject to inherent selection bias. The reported results describe observed associations and do not demonstrate a direct cause and effect relationship between analyzed criteria and surgical mortality. The de-identified nature of the dataset did not allow for the analysis of certain data. In these analyses, we utilized available data within the VCSQI de-identified data registry to proxy similar criteria as that utilized in the REALISM criteria. Certain REALISM trial criteria could not be assessed (eg, presence of porcelain aorta or mobile ascending aortic atheroma, cirrhosis, or previous mediastinitis) as these factors were not were not available within the analyzed dataset. Similarly, we could not analyze data with respect to mitral valve morphology or etiology of disease. It is important to note that the STS PROM score does have predictive limitations, and REALISM trial developers were attempting to better define those serious risk factors not well accounted for in the STS score. Furthermore, MitraClip is currently approved for degenerative MR while patients with functional MR who are not appropriate for surgery are currently eligible for the Cardiovascular Outcomes Assessment of the MitraClip Therapy Percutaneous Therapy for High Surgical Risk Patients (COAPT) trial [15] . All analyses were limited to short-term, operative outcomes, and long-term follow-up related to success and durability of MV repair or replacement was not available. Finally, unrecognized miscoding of data must also be considered in any secondary analysis of a data registry.
The present results suggest that certain REALISM criteria used to identify patients at high risk for surgery, including reoperation with patent grafts and functional mitral regurgitation þ EF less than 0.40 may not accurately represent patients at high risk of death with surgery. The REALISM trial inclusion criteria may not be indications for MitraClip instead of surgery. Patients with STS PROM greater than 12% and those with 3 or greater established STS high-risk criteria appear to be at increased risk for surgical mortality after mitral valve repair or replacement. However, in addition to conventional STS criteria, these data suggest that risk assessment by surgeons is essential to direct appropriate treatment allocation for high-risk mitral disease.
We would like to thank George J. Stukenborg, PhD for his statistical mentorship.
DISCUSSION
DR L. WILEY NIFONG (Greenville, NC): Thanks, Gorav, for bringing all of that to our attention. Do you think, related to the MitraClip in the future, that a lot of these high-risk patients will have the MitraClip, is that the direction in which we're going, or are we just trying to prove that our STS [The Society of Thoracic Surgeons] scoring is correct?
DR AILAWADI: The real take-home message is that we, as a surgical community, need to be involved in patient selection, at the very least, if not in the MitraClip procedure itself. If we let it go by the wayside and, as is happening now, surgeons are not involved in patient selection, in saying any given patient is not appropriate for surgery. For me, that is the real important takehome point. I do think there is a role for novel therapies whether it's MitraClip or other new technologies in high-risk patients, and I think we need to be careful about what may be considered high-risk criteria, by the lay public, by cardiologists, is not really high risk by our eye.
DR DANIEL DRAKE (Traverse City, MI): I direct the Michigan Society of Thoracic and Cardiovascular Surgeons Mitral Initiative. Thank you for your excellent presentation. Your work will expedite ours considerably. My question relates your work to the 2005 New England Journal of Medicine publication by Sarano and the group at the Mayo Clinic which demonstrated a substantially increased mortality associated with moderate mitral regurgitation. At 5 years, an additional one-third of patients with moderate regurgitation were dead. Yet moderate regurgitation following MitraClip placement is so common it is almost the norm. How do you reconcile the residual regurgitation and presumably increased mortality associated with this device? DR AILAWADI: Great question. I am well aware of the excellent studies from the Mayo group. I think leaving residual moderate MR [mitral regurgitation] is a valid point and we still do not know. I can tell you that based on later outcomes that are being published from the EVEREST trial and REALISM is that we do not see that detriment yet in patients with moderate MR, at least after 4 and 5 years. Maybe we will see that effect later.
On the flip side, because these patients never really undergo surgery, they do not feel quite as bad as patients that undergo surgery. There really does appear to be some biologic effect of patients undergoing whether it be minimally invasive or sternotomy surgery, that maybe they do not quite get back. So I think that still remains to be determined.
The counterargument, of course, is that these patients that we are offering MitraClip to, a lot of them are not going to live 5, 8, 10 years.
Ultimately, we as surgeons need to decide what is best for a patient. We must be able to offer the full range of therapies ourselves so there is no bias for surgery or clip.
DR ERNESTO JIMENEZ (Tampa, FL): Unfortunately, you did not describe any risk stratification for patients with liver disease. As a VA [Veterans Administration] surgeon who operates on people who are alcoholic, hepatitis C, and very, very bad livers, it is a real dilemma in terms of whether or not we, in addition to those, how we assess those patients. Do you use the Child-Pugh criteria, the MELD [Model for End-Stage Liver Disease] score, an ultrasound to check for portal vein flow, portal vein open, varices? All that stuff is not really, there is no data on that. Maybe a risk score can help us with that.
Number two; people who are on dialysis, who may need a mitral valve operation, what are their risks, long-term assessment for those patients? And those patients all have calcium along that valve. I mean, is that going to be added to the risk assessment?
DR AILAWADI: You very well highlight the reasons why surgeons need to be involved in identifying these patients. Currently, liver disease is not captured in the STS. There is some measure of liver disease in the EuroSCORE [European system for cardiac operative risk evaluation] calculator. I think every center has developed their own practice. We get our hepatologist involved early on to evaluate and sometimes get a liver biopsy. They certainly get endoscopy to make sure they do not have esophageal varices. We have looked at MELD, particularly as it pertains to tricuspid valve surgery and saw a very dramatic effect in association between MELD and mortality and that has translated into us using MELD to stratify any patients undergoing cardiac surgery. So I believe there is likely a link. Since this is not in the STS database, we cannot use that risk assessment alone and we need to select patients for the appropriate therapy.
In terms of the second part relating to patients on dialysis, there are two important points we ought to discuss. One is data from Dr Thourani at Emory looked at long-term mortality with patients undergoing valve replacement, whether it was aortic or mitral. They found on average about half of them are dead at 2 years after valve surgery. And I think that is important. We do not really have a good treatment option for these patients.
On the flip side, MitraClip, we have actually seen 1 patient develop pretty aggressive calcification of their mitral valve after MitraClip in a dialysis patient that ultimately led to mitral stenosis several years later. So I am not sure we have got a good answer for that. It may not be using the technologies that we currently have. DR AILAWADI: All of you know the database as well as anybody, we all use it daily. I think the things that play the biggest role are renal insufficiency. Reoperation does not add a whole lot, it adds some. The other things that play a big role are other things; carotid disease, vascular disease, female gender. And in terms of the REALISM trial, many of you may not know to get patients to qualify, actually you had to put in mitral replacement, not repair, in the STS predict the risk. That automatically adds a couple points to their risk.
DR VALAVANUR SUBRAMANIAN
DR PATRICK MCCARTHY (Chicago, IL): The REALISM trial really was not very good, to be honest. I was involved in the interpretation of the data to the FDA [Food and Drug Administration] panel, and members from STS and others spoke on behalf of approving MitraClip. I would just point out that the criteria that were in REALISM were not the only criteria, because the patients were reviewed by surgeons. And so an example, one patient that did not appear to be high risk had a prior stroke, which may not be a big deal, but that patient was literally paralyzed and wheelchair bound so that that was how they ended up in the trial. Other patients, for instance, were on chemotherapy because they had metastatic cancer.
The STS database and the scoring systems are great at judging risk in the middle of the bell-shaped curve. But as surgeons we all see outliers, those patients that have comorbidities that are really important and really significant.
I would reassure the audience that with commercial approval of MitraClip it is not going to be as loose as the REALISM criteria; all of those patients will have to be seen and approved by a surgeon. And if there is any way that the patient is a surgical candidate, then the patient should receive surgery.
Dr Ailawadi, do you want to speak to the commercial approval and how you think that will play out for candidates?
DR AILAWADI: As many of you know, the FDA approved patients with degenerative MR who are not appropriate candidates or are at exceedingly high risk for surgery. Most of us have developed that assessment through our local heart teams, and I think that's very important as we move forward. The surgeon needs to be absolutely a critical player in that, in patient selection, as Dr McCarthy mentioned. We cannot just use the STS, that is merely a guideline. And what some people consider high risk, particularly in the REALISM trial, really is not high risk.
On the flip side, there are many things that the STS does not capture that we just realize that it is futile to operate on. And so I think the heart team is critical to deciding this. We need to be active and a part of it, and I think we need to push to actually get to the table to be doing the procedure as well. We as surgeons have the ability to be unbiased and be able to offer a patient a sternotomy, a mini, or a MitraClip.
